Supplementary Figure 1 from Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition by Anthony S. Fischl (15070804)

Regression results using the difference between first and last substance dependence scale (SDS) scores as the criterion (n = 1648; reference categories: male, non-Aboriginal and/or... by Theresa Caruana (15628074)

Subjects:

Mean psychological distress (K10) score by days since intake, grouped by intake tertiles (from least to most distressed), routine service clinical intervention dataset 2014 to 2020... by Theresa Caruana (15628074)

Subjects:

Statistically significant changes between assessments for substance dependence (SDS), psychological distress (K10), and quality of life (EQoL) at four standardised timepoints, rout... by Theresa Caruana (15628074)

Subjects:

Mean quality of life (EQoL) score by days since intake, grouped by intake tertiles (from lowest to highest quality of life) routine service clinical intervention dataset 2014 to 20... by Theresa Caruana (15628074)

Subjects:

Mean substance dependence (SDS) score by days since intake, grouped by intake tertiles (from least to most dependent), routine service clinical intervention dataset 2014 to 2020 (n... by Theresa Caruana (15628074)

Subjects:

Intake demographic characteristics and time in service, routine service clinical intervention dataset, 2014 to 2020 (n = 3893). by Theresa Caruana (15628074)

Subjects:

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders by Diane Nugent (14796787)

“…</p> <p>WG3 identified three focus areas with the potential to advance the needs of all people with ultra-rare inherited BDs and scored the feasibility, impact, and risk of priority initiatives, including 13 in systems biology and mechanistic science; 2 in clinical research, data collection, and research infrastructure; and 5 in the regulatory process for novel therapeutics and required data collection.…”

FASN Expression in OA and RA–shows that FASN is also significantly downregulated in the disease groups for OA and RA, suggesting its decreased activity might influence disease mech... by Chang-sheng Liao (18591969)

Subjects:

Stability and decrease rate of resistance to methoxyfenozide and other tested insecticides in <i>Chrysoperla carnea</i>. by Muhammad Mudassir Mansoor (12275345)

“…<p>Stability and decrease rate of resistance to methoxyfenozide and other tested insecticides in <i>Chrysoperla carnea</i>.…”

FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro... by Lisa Marie Fröhlich (16838353)

“…<p>MAPKi resistant cells show decreased ATM expression. <b>A,</b> Immunoblot analysis of A375 R cells treated with 5 μmol/L talazoparib (Tala.) for 24 hours or untreated (Ctr.). …”

Figure S1, S2, S3, S4, S5, S6, S7, S8, and S9 from <i>ARID5B</i> Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia by Heng Xu (244639)

“…<p>Figure S1 shows the knock-down effect of ARID5B with different shRNAs in Nalm6 cells; Figure S2 shows the correlation between MTX and 6-MP sensitivity with different levels of ARID5B knock-down in Nalm6 cells; Figure S3 shows that down-regulation of ARID5B mediated MTX and 6-MP drug resistance can be reversed by re-expression of ARID5B; Figure S4 shows that the levels of MTX and 6-MP active metabolites were reduced significantly after ARID5B knockdown; Figure S5 shows similar MTX and 6-MP drug resistance after CRISPR-mediated ARID5B downregulation; Figure S6 shows that decreased cell growth was detected by BrdU-uptake assay; Figure S7 shows treatment with increased concentrations of MTX and 6-MP led to gradually decreased p21 level; Figure S8 shows that a potential ARID5B binding site 25kb distal to CDKN1A locus was identified by ATAC-seq signal and Histone modification marks; Figure S9 shows an enrichment of components of the p53 signaling pathway was differentially expressed upon ARID5B knockdown.…”

Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers by Meghan Morrison Joly (4218496)

“…Cells were treated 6h with PP242 (1μM) ± lapatinib (1μM) and assessed by luminescent caspase-3/7 assay.…”

Supplementary figure S1 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models by Soon Young Park (14978769)

Reversion to susceptibility was consistent with decreasing relative <i>vanA</i> copy number. by Samuel E. Blechman (19506884)

Supplementary Fig. S8 from Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa Expression by Azusa Tanimoto (14936243)

Supplemental Figure S6 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma by Shaofang Wu (14936085)

Syndecan ectodomain fragments decrease endothelial resistance via rho kinase. by Melanie Jannaway (6703577)

“…(E) Pretreatment with Y27632 (10 μM, 1hr) significantly inhibits S3ED fragment-induced decreases in peak TER change (n = 4, p = 0.0045). …”

Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)